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1. Introduction 
Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disease 
characterized by left ventricular wall thickening, myofilament disarray and abnormal 
echocardiography findings. Molecular genetic studies have defined FHC as a disease of the 
sarcomere caused by mutations in all major sarcomeric proteins, such as ǃ-myosin heavy 
chain (44%), myosin binding protein C (35%), regulatory light chain (2%), essential light 
chain (1.6%), ǂ-tropomyosin (2.5%), troponin T (7%), troponin I (5%), troponin C (~1%), ǂ-
actin (1%), and titin (<1%) (Alcalai et al., 2008).  
Although mutations in the regulatory light chain (RLC) of myosin are rare, they are of 
great significance given the importance of RLC for muscle contraction and heart function. 
The RLC plays an essential structural and functional role by supporting the architecture of 
the myosin neck region and fine-tuning the kinetics of the actin-myosin interaction 
(Morano, 1999; Szczesna, 2003). As shown in Fig. 1, the RLC wraps around the ǂ-helical 
neck region of the myosin head by binding to a 35 amino acid IQ motif in the myosin 
heavy chain (MHC) (Rayment et al., 1993). This domain of MHC is anticipated to act as a 
lever arm, amplifying small conformational changes that originate at the catalytic site into 
large movements thus allowing myosin to generate motion and force (Geeves & Holmes, 
2005; Lowey et al., 1993). Furthermore, this neck region has been proposed to serve as the 
compliant element of the myosin cross-bridge with the RLC contributing to the stiffness of 
the lever arm (Howard & Spudich, 1996; Pant et al., 2009). Two functionally important 
domains of the RLC molecule include its Ca2+-Mg2+ binding site, comprised of the N-
terminal helix-loop-helix EF-hand Ca2+ binding motif, and a highly conserved N-terminal 
phosphorylatable serine constituting a myosin light chain kinase (MLCK)-dependent 
phosphorylation site.  
The N-terminal divalent cation-binding site of the RLC is thought to be occupied by Mg2+ 
when muscles are in the relaxed state and may become partially saturated with Ca2+, 
depending on the length of the [Ca2+] transient (Robertson et al., 1981). The MLCK 
phosphorylation site of RLC is also of great structural and functional importance. 
Phosphorylation of this site in smooth muscle activates contraction (Hartshorne & Mrwa, 
1982; Small & Sobieszek, 1977; Sobieszek, 1977). In skeletal and cardiac muscle, Ca2+-
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calmodulin (CaM) activated MLCK phosphorylation of RLC modulates contraction by 
increasing the Ca2+ sensitivity and the level of force and also by modulating the kinetics of 
force generating myosin cross-bridges (for review see (Kamm & Stull, 2011)). Of particular 
importance, the phosphorylation of RLC has been shown to regulate the function of 
myosin in the heart (Morano, 1999; Szczesna, 2003). Attenuation of RLC phosphorylation 
was demonstrated to lead to ventricular myocyte hypertrophy with histological evidence 
of necrosis and fibrosis (Ding et al., 2010). Recent results from Szczesna-Cordary’s lab 
shown that RLC phosphorylation plays an essential role not only in the physiological 
performance of the heart, but also helps to maintain normal cardiac function in the 
diseased myocardium (Muthu et al., 2011). At the level of protein, the phosphorylation of 
RLC at Ser-15 was shown to alter the secondary structure (ǂ-helical content) and Ca2+ 
binding affinity of the human ventricular RLC protein (Szczesna et al., 2001). At the level 
of myofilaments, RLC phosphorylation was demonstrated to result in a significantly 
decreased distance between the myosin heads and actin filaments bringing them closer to 
each other (Colson et al., 2010) 
 
 
Fig. 1. Schematic representation of the myosin head (cross-bridge) containing regulatory 
(RLC, labeled in magenta) and essential (ELC, labeled in yellow) light chains. Indicated 
are 1) motor domain, and 2) lever arm (Rayment et al., 1993). 
1.1 FHC-linked mutations in the regulatory light chain (RLC) 
To date, eight single point mutations and two intron alternative splicing mutations in the 
MYL2 gene encoding for the human ventricular RLC (Swiss-Prot: P10916) have been 
identified to cause FHC (Fig. 2). They are A13T (alanine to threonine), F18L (phenylalanine 
to leucine), E22K (glutamic acid to lysine), N47K (asparagine to lysine), R58Q (arginine to 
glutamine), P95A (proline to alanine), K104E (lysine to glutamic acid), D166V (aspartic acid 
to valine), IVS5-2 (a A>G transversion in intron 5 that leads to a premature termination 
codon), and IVS6-1 (a G>C transversion in the acceptor splice site of intron 6). 
The A13T mutation arises from a replacement of alanine, an uncharged and nonpolar amino 
acid by threonine, an uncharged but polar amino acid. The mutation was first discovered in an 
American patient (Poetter et al., 1996) and was later found in a Danish proband diagnosed 
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with hypertrophic cardiomyopathy (HCM). Two of his family members were found to be 
heterozygous for the mutation (Andersen et al., 2001). The proband, 42 years old, suffered 
from exercise-induced dyspnoea and had pronounced septal hypertrophy, diastolic filling 
abnormities but no significantly increased left ventricular outflow tract. One of the family 
members, the mother of the proband, was diagnosed with HCM late in life and died at the age 
of 72; while the other, 10 years old, showed no sign of HCM. In 2005, another proband 
carrying the A13T mutation was also identified in a Danish population (Hougs et al., 2005). 
Overall, this mutation is associated with a rare HCM phenotype characterized by mid left 
ventricular obstruction, enlarged papillary muscles and profound septal hypertrophy.  
 
 
Fig. 2. Exon organization of the MYL2 gene (chromosome 12q23-q24.3) and FHC-linked 
mutations in human ventricular RLC (Swiss-Prot: P10916). Labeled in red, FHC mutations 
described in this review; in black, other identified RLC mutations; and in green, intronic 
splice site mutations: A (adenine)  G (guanine) transversion in intron 5 and G  C 
(cytosine) transversion in intron 6. 
The F18L mutation arises from a replacement of a bulky nonpolar and hydrophobic 
phenylalanine by the small uncharged and nonpolar leucine residue. It was found in three 
unrelated French families and is associated with a classic phenotype of left ventricular wall 
thickening and electrocardiographic (ECG) abnormities (Richard et al., 2003). 
The E22K mutation results from a substitution of a negatively charged glutamate with a 
positively charged lysine leading to potential alterations in the net charge and polarity of the 
mutation-bearing domain of RLC. The mutation was first identified in three persons (two 
brothers and one non-related individual) from two unrelated families screened together 
with 399 unrelated HCM patients (Poetter et al., 1996).  Subsequent studies by Kabaeva, et 
al. identified seven individuals in a German family carrying the mutation. However, only 
four patients suffered from HCM while the phenotype of the remaining individuals was 
defined as "uncertain" (Kabaeva et al., 2002). Based on the latest clinical reports on this 
mutation, it is known to be associated with moderate septal hypertrophy, late onset of 
clinical manifestations, and benign to severe disease outcomes.  
The N47K mutation results from the replacement of a polar uncharged asparagine residue 
by the positively charged lysine. It was first discovered in an individual of Danish descent 
(Andersen et al., 2001). This mutation is associated with a late onset of the disease and a 
rapidly progressing phenotype. The proband was diagnosed with HCM at the age of 60, and 
quickly progressed to a severe hypertrophic phenotype and diastolic dysfunction. It was 
interesting that septal hypertrophy of this patient increased rapidly (from 31 mm to 45 mm) 
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in the two years after diagnosis. In 2005, a Danish patient carrying both N47K and a ǃ-
cardiac myosin heavy chain mutation was identified. The proband bearing both of these 
mutations displayed a more severe phenotype than patients with either mutation alone 
(Hougs et al., 2005). However, no incidence of sudden cardiac death (SCD) associated with 
this mutation has yet been reported.  
The R58Q mutation occurs when the bulky positively charged arginine is replaced by an 
uncharged but polar glutamine. It was first discovered by Flavigny, et al. in 1998 in three 
unrelated French families with HCM (Flavigny et al., 1998). The mutation was associated 
with a classic form of FHC characterized by left ventricular wall thickness, abnormal ECG 
findings and SCD (Flavigny et al., 1998). In 2002, Kabaeva, et al. detected this R58Q 
mutation in a German proband with a clinical phenotype of moderate septal hypertrophy, 
early onset of disease and premature SCD (Kabaeva et al., 2002). In 2003, the R58Q mutation 
was once more identified in two independent population studies (from France and Sweden), 
and again was associated with a malignant disease phenotype (Morner et al., 2003; Richard 
et al., 2003). Out of all identified FHC RLC mutations, the R58Q mutation was found to be 
the most prevalent, occurring independently in multiple families with different ethnic 
backgrounds. The mutation is associated with a phenotype of severe cardiac hypertrophy 
and multiple incidences of SCD. 
The P95A mutation occurs when a bulky hydrophobic proline residue is substituted with a 
smaller alanine residue. It was discovered together with the A13T and E22K mutations in an 
American family and shares a rare clinical phenotype, similar to that of A13T and E22K 
positive patients (Poetter et al., 1996). 
The K104E mutation results from a replacement of the positively charged lysine with the 
negatively charged glutamic acid. The mutation was first observed in a Danish family and 
was mistakenly reported as L103E (Andersen et al., 2001). The parents carrying this 
mutation were asymptomatic with a normal ECG pattern. However, their son was 
diagnosed with pronounced septal hypertrophy at the age of 17 and progressed to diastolic 
dysfunction. His sister, 42 years old, was also positive for the mutation, but no typical 
hypertrophic phenotype was observed in her case. This mutation is associated with 
pronounced septal hypertrophy and diastolic filling abnormalities.  
The D166V mutation occurs when a negatively charged aspartic acid is substituted with a 
bulky polar valine residue. This mutation was identified in a French proband, with the 
potential to cause SCD at a young age. It was first mistakenly presented as D166L in 
Richard, et al., 2003 and later corrected to D166V (Richard et al., 2003; 2004). Similar to 
R58Q, this mutation is associated with a malignant disease phenotype and SCD.  
Intron mutations: Intron 6-1 G>C mutation (IVS 6-1) was discovered along with K104E in 
the Danish population and is associated with pronounced septal hypertrophy (Andersen et 
al., 2001). The other intronic mutation 5-2 A>G, (IVS 5-2) was first discovered in the French 
population and is associated with a malignant form of FHC (Richard et al., 2003). The 
mutation is predicted to lead to a premature codon termination. 
The clinical phenotype associated with FHC-linked mutations in the regulatory light chain 
and current to date literature citations are illustrated in Table 1.  
This review focuses on the functional phenotypes associated with five (A13T, E22K, N47K, 
R58Q and D166V) RLC mutations extensively studied in vitro using RLC-mutant 
reconstituted muscle systems and in vivo, using cardiac muscle preparations from transgenic 
mice expressing FHC-RLC mutations.  
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Mutation in 
RLC 
Clinical phenotype Population Major findings 
A13T 
Massive hypertrophy 
of cardiac papillary 
muscles, mid-cavity 
left ventricular 
obstruction, 
pronounced septal and 
ventricular 
hypertrophy and 
diastolic filling 
abnormalities 
Danish 
(Andersen et 
al., 2001; 
Hougs et al., 
2005); 
American 
(Poetter et al., 
1996) 
Mutation-induced changes in  -helical content and in 
Ca2+ binding properties of RLC (Szczesna et al., 
2001). 
No change in Ca2+sensitivity of myofibrillar ATPase 
activity (Szczesna et al., 2001). 
Increased force production in skinned papillary 
muscle fibers from Tg-A13T mice (unpublished 
data). 
Histopathological changes in left ventricles and inter-
ventricular septa of Tg-A13T mice (unpublished 
data) 
F18L 
Classic form of HCM – 
increased left 
ventricular wall 
thickness, abnormal 
ECG findings, no mid 
left ventricular 
obstruction 
French 
(Flavigny et al., 
1998; Richard 
et al., 2003) 
Decrease in Ca2+ binding affinity to RLC (Szczesna et 
al., 2001). 
Increase  in ǂ-helical content of RLC (Szczesna et al., 
2001). 
Decrease in Ca2+ sensivity of myofibrillar ATPase 
activity (Szczesna-Cordary et al., 2004a). 
Compromised maximal tension, cooperativity and Ca2+ 
sensitivity of force (Roopnarine, 2003). 
E22K 
Moderate septal 
hypertrophy, late onset 
of clinical 
manifestation or no 
symptoms of FHC 
(Kabaeva). Also 
associated with 
massive hypertrophy 
of cardiac papillary 
muscles and adjacent 
venstricular tissue 
causing midcavity 
obstruction (Poetter) 
German 
(Kabaeva et al., 
2002), 
American 
(Poetter et al., 
1996) 
Protein non-phosphorylatable (Szczesna et al., 2001). 
Mutation induced changes in -helical content and 
Ca2+ binding properties of RLC (Szczesna et al., 
2001). 
Increase in Ca2+ sensitivity of force (Levine et al., 1998; 
Roopnarine, 2003; Szczesna-Cordary et al., 2004a) 
and decrease in maximal ATPase and force in 
skinned fibers from Tg-E22K mice (Szczesna-
Cordary et al., 2007). 
No effect on cross-bridge kinetics (Szczesna-Cordary et 
al., 2007; (Dumka et al., 2006). 
Enlarged inter-ventricular septa and papillary muscles 
(Szczesna-Cordary et al., 2005). 
No hypertrophy detected in Tg-E22K mice (Sanbe et al., 
2000). 
No changes in ECG (Szczesna-Cordary et al., 2005). 
N47K 
Pronounced 
interventricular 
(septal) and papillary 
musle hypertrophy; 
relatively high  
midventricular flow 
gradient, diastolic 
filling abnormalities; 
late onset disease with 
a rapidly progressing 
phenotype 
Danish 
(Andersen et 
al., 2001; 
Hougs et al., 
2005) 
Abolished Ca2+ binding to RLC (Szczesna-Cordary et 
al., 2004a). 
Increased Ca2+ sensivity of myofibrillar ATPase activity 
(Szczesna-Cordary et al., 2004a). 
No change in pCa50 of force (Szczesna-Cordary et al., 
2004a). 
Prolonged Ca2+ transient with no change in force 
transients in intact papillary muslces (Wang et al., 
2006). 
Decreased isometric force in N47K-myosin based in 
vitro motility assays (Greenberg et al., 2009). 
Reduction in force and power output under loaded 
conditions (Greenberg et al., 2010). 
Decreased cardiac function in isolated perfused 
working hearts (Abraham et al., 2009). 
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Mutation in 
RLC 
Clinical phenotype Population Major findings 
R58Q 
Malignant FHC 
phenotype, early onset 
of clinical 
manifestation and high 
incidence of premature 
SCD; classic form of 
HCM - increased left 
ventricular wall 
thickness and 
abnormal  ECG 
findings 
German 
(Kabaeva et al., 
2002), French 
(Flavigny et al., 
1998; Richard 
et al., 2003), 
Swedish ( 
Morner et al., 
2003) 
Abolished Ca2+ binding to RLC, which was restored 
upon RLC phosphorylation. (Szczesna et al., 
2001). 
Mutation induced increase in ǂ-helical content of RLC 
(Szczesna et al., 2001). 
Increased Ca2+ sensitivity of force (Szczesna-Cordary et 
al., 2004a), and Ca2+ and force transient in intact 
papillary muscles (Wang et al., 2006). 
Higher ATPase rate and increased activation at 
submaximal Ca2+ (Greenberg et al., 2009). 
Decreased skewness and kurtosis of fluctuations 
during contraction (Borejdo et al., 2010). 
Decreased force (Abraham et al., 2009; Greenberg et al., 
2010; Greenberg et al., 2009; Wang et al., 2006). 
Reduced level of endogenous RLC phosphorylation 
(Abraham et al., 2009). 
Decreased cardiac function in isolated perfused 
working hearts (Abraham et al., 2009). 
Alterations in diastolic transmitral velocities and 
increased deceleration time, indicative of diastolic 
dysfunction (Abraham et al., 2009). 
P95A 
Rare clinical 
phenotype, similar to 
E22K and A13T, of 
midventricular 
obstruction 
American 
(Poetter et al., 
1996) 
Mutation-induced decrease in Ca2+  binding to RLC 
(Szczesna et al., 2001). 
No significant effect on tension, Ca2+ sensitivity, or 
cooperativity in P95A-reconstituted  fibers 
(Roopnarine, 2003). 
K104E 
Pronounced septal 
hypertrophy and 
diastolic filling 
abnormalities 
Danish 
(Andersen et 
al., 2001) 
Impaired interaction with  IQ-MHC peptide (Szczesna-
Cordary et al., 2004b). 
Slight decrease in binding to RLC-depleted porcine 
myosin (Huang et al., 2011). 
D166V 
Malignant FHC 
phenotype - poor 
prognosis and SCD at 
young age 
French 
(Richard et al., 
2003; 2004) 
Decrease in maximal force and large increase in Ca2+ 
sensitivity in papillary muscle fibers from Tg-
D166V mice (Kerrick et al., 2009). 
Decrease in Ca2+ sensitivity of force upon 
phosphorylation (Muthu et al., 2011). 
Slower cross bridge kinetics (Borejdo et al., 2010; 
Mettikolla et al., 2009; Muthu et al., 2010). 
Reduced level of endogenous RLC phosphorylation 
(Kerrick et al., 2009). 
Severe fibrotic lesions in older Tg-D166V mouse hearts 
(Kerrick et al., 2009). 
IVS6-1 
Pronounced proximal 
septal hypertrophy 
Danish 
(Andersen et 
al., 2001) 
G>C transversion in Intron 6 (Andersen et al., 2001). 
IVS5-2 Malignant prognosis 
French 
(Richard et al., 
2003) 
Donor-site splice mutation (A>G) in Intron 5 predicted 
to lead to a premature termination codon (Richard 
et al., 2003). 
Table 1. Summary of clinical and functional phenotypes of FHC mutations in the regulatory 
light chain (RLC).  
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2. Effect of FHC mutations on the secondary RLC structure and calcium 
binding properties 
This review reports on the studies that were conducted to elucidate the structural and 
functional effects of FHC-linked RLC mutations. The RLC protein, labeled in red in Fig. 3, 
wraps around the myosin heavy chain (dark blue) and connects the myosin head with the 
myosin rod region. The three-dimensional (3D) structure of the RLC demonstrates the close 
proximity of the FHC mutations to either the phosphorylation site of RLC (Ser-15) or the 
Ca2+ binding site (amino acids 37–48 in the sequence of human ventricual RLC) (Fig. 3). The 
presence of these two important RLC domains in the RLC structure  prompted the studies 
aimed at understanding the effects of the FHC mutations on Ca2+ binding to RLC and to 
determine how MLCK-dependent phosphorylation of RLC is affected in FHC disease. 
Furthermore, additional studies were conducted to determine the effect of FHC-linked RLC 
mutation and phosphorylation on the secondary RLC structure.   
 
 
Fig. 3. Structure of the regulatory domain of scallop myosin (1WDC) (Houdusse & Cohen, 
1996): Indicated are the FHC mutations, Ca2+-Mg2+ binding site and the phosphorylation 
site.  The MHC (myosin heavy chain) is labeled in dark blue, and the RLC (regulatory light 
chain) in red. Asterisks (*) depict the predicted location of A13T and F18L mutations and 
Ser-15 phosphorylation site (the region of RLC which is not resolved in all available 
vertebrate myosin crystal structures). 
2.1 Circular dichroism study 
In order to test the effect of RLC mutations on the secondary structure of RLC, far-UV 
circular dichroism (CD) spectra measurements were performed and the ǂ-helical content 
determined (Szczesna-Cordary et al., 2004a; Szczesna et al., 2001). Far-UV CD spectra were 
obtained using a 1-mm path quartz cell in a Jasco J-720 spectropolarimeter and were 
recorded at 195–250 nm. Mean residue ellipticity ([θ]MRE, in degrees *cm2/dmol) for the 
spectra were calculated using the following equation: 
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[θ]MRE=[θ]/(10*Cr*l) 
where [θ] is the measured ellipticity in millidegrees, Cr is the mean residue molar 
concentration, and l is the path length in cm.  
The ǂ-helical content for each mutant was calculated using the standard equation for [θ] at 
222 nm (Chen & Yang, 1971):  
[θ]222=-30,000*fH – 2340 
where fH is the fraction of ǂ-helical content (fH * 100, expressed in %).  Any change above 2% 
in the ǂ -helical content was considered statistically significant. 
As the mutations lie in the proximity of the phosphorylation site (Ser-15) and/or the Ca2+-
Mg2+ binding site (Fig. 3), the ǂ-helical content was measured in the absence (Apo) and 
presence of Ca2+. In addition, data were collected for phosphorylated RLC (Table 2). 
 
Protein Apo +Ca2+ +P +P +Ca2+ 
RLC-WT 18 23 18 18 
A13T 29 25 19 18 
E22K 24 20 No phosphorylation 
N47K 18.7 ND ND ND 
R58Q 20 22 20 28 
P95A 19 23 ND ND 
Table 2. Effect of phosphorylation and Ca2+-binding on the ǂ-helical content of RLC 
expressed in %. (ND: not determined) (Szczesna-Cordary et al., 2004a; Szczesna et al., 2001). 
Based on these results, it was determined that under Apo (no metal) conditions, with the 
exception of the N47K and P95A mutants, the FHC-linked RLC mutation led to an increased 
ǂ-helical content compared to RLC-WT (Szczesna-Cordary et al., 2004a; Szczesna et al., 
2001). It was also observed that upon binding of Ca2+ to RLC, the ǂ-helical content was 
significantly increased in all proteins including WT (Table 2), suggesting that binding of 
calcium to RLC could be conformation dependent. Interestingly, upon phosphorylation, 
A13T displayed a significant decrease in the ǂ-helical content compared to non-
phosphorylated A13T in the presence or absence of Ca2+.  Therefore, phosphorylation of the 
A13T mutant rescued the secondary structure of the mutant bringing the ǂ-helical content to 
the level of RLC-WT. The authors concluded that phosphorylation of RLC could reverse the 
detrimental effect of FHC brought about by the A13T mutation (Szczesna et al., 2001).  
2.2 Calcium binding study 
As shown above in Fig. 3, the N-terminal domain of RLC contains the EF-hand Ca2+-Mg2+ 
binding site, similar to the EF-hand Ca2+-sites present in troponin C (TnC), parvalbumin, 
calmodulin (CaM) and essential light chain (ELC). To test how these mutations affect 
calcium binding to the RLC, flow dialysis experiments were conducted and the Ca2+ 
association/dissociation constant was determined (Szczesna et al., 2001). Radio-labeled 
substrate (45Ca2+) was first added into a chamber containing a fixed amount of RLC. Once 
the reaction reached steady-state, radio-labeled 45Ca2+ was chased by unlabeled Ca2+. The 
concentrations of bound-Ca2+ and free-Ca2+ were determined and the KCa values analyzed. 
Calcium association constant KCa was extrapolated from the following equation: 
CCa-bound/CCa-free/Cp =-KCa* CCa-bound/Cp+ n*KCa 
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CCa-bound and CCa-free represent the concentration of the bound and free metal, respectively, Cp is 
the concentration of the protein, n is the total number of Ca2+ binding sites, and KCa is the Ca2+ 
binding affinity. 1/KCa represents the apparent calcium dissociation constant Kd (in μM). The 
effect of the mutations on calcium binding to recombinant human cardiac RLC and FHC-
linked mutants is summarized in Table 3 (Szczesna et al., 2001). Table 3 also summarizes the 
effect of FHC RLC mutations on calcium binding to myofibrils and skinned muscle fibers 
reconstituted with WT or FHC-mutant proteins (Szczesna-Cordary et al., 2004a).  
 
RLC protein 
Isolated RLC  (no 
Mg2+) 
(µM) 
Myofibrils# 
(2 mM Mg2+) 
(µM) 
Fibers# 
(1 mMMg2+) 
(µM) 
RLC-WT 1.50 ± 0.02 0.200 ± 0.009 2.88 ± 0.19 
A13T 4.85 ± 0.31 0.191 ± 0.015 3.02 ± 0.06 
E22K 25.64 ± 3.48 0.178 ± 0.001 2.63 ± 0.10 
N47K No binding 0.141 ± 0.009 2.51 ± 0.10 
R58Q No binding 0.170 ± 0.004 2.19 ± 0.10 
P95A 4.74 ± 1.05 0.200 ± 0.011 2.75 ± 0.25 
Table 3. Apparent Kd (1/KCa) of isolated RLC-WT and FHC mutants and in mutant-
reconstituted myofibrils and skinned porcine muscle fibers (#Kd calculated from the pCa50 
values ±S.E.) (Szczesna-Cordary et al., 2004a). 
Flow dialysis experiments with recombinant RLC-WT and FHC-mutants showed that A13T 
and P95A decreased the KCa ~3-fold, whereas E22K, N47K and R58Q, changed the Ca2+ binding 
properties in a more drastic way. Compared with RLC-WT, the E22K mutation decreased the 
KCa value by ~17-fold, whereas both N47K and R58Q mutations eliminated Ca2+ binding to RLC 
(Table 3) (Szczesna et al., 2001). These three Ca2+ binding site mutants also showed an increase 
in the Ca2+ sensitivity of myofibrillar ATPase activity and force development, with R58Q 
demonstrating significantly higher KCa compared to RLC WT-reconstituted muscle 
preparations (Table 3) (Szczesna-Cordary et al., 2004a). Interestingly, flow dialysis studies 
showed that the restricted ability of the R58Q mutant to bind calcium was restored upon 
phosphorylation (Szczesna et al., 2001). These studies suggested that the phosphorylation and 
Ca2+ binding to human cardiac RLC are important for physiological function and that alteration 
of any of these properties may contribute to the development of hypertrophic cardiomyopathy.  
Results from the in vitro studies prompted generation of the animal models of FHC-linked RLC 
mutations and subsequent investigations of their functional effects in vivo. Studies included 
experiments performed at different levels of complexity; from single molecules to organized 
sarcomeres in muscle fibers and to the organ and organism levels. Transgenic mice carrying 
FHC RLC mutations were used in these experiments.  
3. Animal models of FHC 
3.1 Generation of transgenic mice 
Transgenic (Tg) mouse models expressing wild-type (WT) and FHC-mutated human 
ventricular cardiac RLC (A13T, E22K, N47K, R58Q and D166V) were generated using the -
myosin heavy chain (-MHC) promoter (clone 26, a generous gift from Dr J. Robbins, 
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA). All of the founders 
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were bred to non-transgenic (NTg) B6SJL mice. Two types of Tg-WT mice were generated as 
necessary controls for the transgenic mutant mice; one expressing human ventricular 
cardiac RLC and another expressing the human ventricular cardiac RLC along with a myc-
tag sequence. The following transgenic mouse models were produced and used for the 
experiments described in this review: WT, A13T, E22K, N47K, R58Q and D166V.  
3.2 Phenotypic characterization of FHC-RLC animal models 
3.2.1 Assessment of cardiac hypertrophy by HW/BW ratio 
The heart weight to body weight (HW/BW) ratio was used to examine all generated FHC 
RLC animal models for heart hypertrophy. Fig. 4 demonstrates the HW/BW ratios 
determined for mice carrying A13T, D166V, N47K and R58Q mutations. No evidence of 
hypertrophy was observed in the majority of mutant mice compared to WT (Kerrick et al., 
2009; Wang et al., 2006). Differences in HW/BW were only seen between the hearts from 
Tg-N47K versus Tg-WT mice, but no statistically significant changes were observed.  
 
 
Fig. 4. Heart weight to body weight ratios in transgenic RLC animal models:  P-values for all 
mutant mice (A13T, D166V, N47K and R58Q) versus WT-RLC were >0.05. 
These results suggested that the histopathological and functional changes observed due to 
these mutations (discussed later) may be more indicative of the FHC phenotype than overall 
heart hypertrophy. 
3.2.2 Histopathology 
The most specific histological feature of hypertrophic cardiomyopathy is an extensive 
disorganization of the myocyte structure (myocyte disarray). Often observed are abnormally 
branched (Y-shaped) myocytes with adjacent myocytes arranged perpendicularly or 
obliquely to each other (Binder et al., 2005). Histological studies were performed to 
characterize the mutation specific cardiac phenotype at the level of the Tg mouse model and 
to establish a correlation with the phenotypes observed in patients harboring these FHC 
RLC mutations.  Histopatological evaluation of the hearts from Tg-A13T, Tg-E22K, Tg-WT 
and NTg mice is presented in Fig. 5.  The upper panel shows longitudinal sections of the 
whole hearts from Tg-A13T versus control mice and the lower panel presents Tg-E22K 
mouse hearts.  As indicated with arrows, a significantly larger LV and inter-ventricular 
septal mass was observed for both Tg-A13T (unpublished data) and Tg-E22K (Szczesna-
Cordary et al., 2005) mice compared with Tg-WT or NTg littermates.  
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Fig. 5. Longitudinal sections of whole mouse hearts stained with hematoxylin and eosin (H 
& E). Upper panel: Tg-A13T versus NTg controls (unpublished data). Bottom panel: Tg-E22K 
and controls (Szczesna-Cordary et al., 2005). Abbreviations: F, female; M, male; mo, age of 
mice in months; LV, left ventricle; IVS, interventricular septum. 
Gross morphological evaluation of the hearts from Tg-A13T and Tg-E22K mice revealed a 
common phenotype of enlarged inter-ventricular septa (Fig. 6), a phenotype observed in 
patients carrying the A13T and E22K mutations (Poetter et al., 1996). Interestingly, in 
another study transgenic mice expressing the E22K mutation did not show any features of 
the FHC disease despite almost total replacement of the endogenous WT RLC with mutant 
RLC (Sanbe et al., 2000). No hypertrophy was detected in mature adult animals either when 
chamber weights were determined or at the cellular level (Sanbe et al., 2000).   
Other RLC FHC mutant mice were examined for histopathological abnormalities, and 
longitudinal ventricular sections were stained with hematoxylin and eosin to detect any 
tissue disorganization and with Masson’s trichrome to determine the presence of abnormal 
collagen deposits and fibrosis. As shown in Fig. 6, mice carrying the malignant R58Q 
mutation manifested histopathological changes (myofibrillar disarray and abnormal 
clustering of nuclei) as early as at 4 months of age (Fig. 6A, B). The changes seen in older 
(~17 months old) mice, presented in Wang et al. were profound in both Tg-R58Q and Tg-
N47K mice (Wang et al., 2006). The changes observed in Tg-N47K mice correlated with the 
phenotype found in humans demonstrating a late onset of disease with a rapidly 
progressing phenotype. Similarly, examination of the older (~17 months of age) Tg-D166V 
mice revealed severe fibrotic lesions present in the left ventricles compared with age 
matched Tg-WT and NTg littermates (Fig. 6C). Morphological changes found in the older 
Tg-D166V mice suggest that the ventricles of the FHC Tg-D166V mice undergo temporal 
phenotypic changes that are not present in the younger mice (~ 7 months of age) (Kerrick et 
al., 2009).  These studies suggested that while in Tg-N47K and Tg-D166V animals the 
functional changes induced by the mutations (evident at 3-6 months of age in mice) may 
precede the development  of any detrimental morphological changes; the histopathological 
changes observed in Tg-R58Q mice paralleled the functional abnormalities.  
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Fig. 6. Histopathology of transgenic mouse hearts. (A) The hearts of representative 4 month-
old mice from Tg-WT, Tg-N47K and Tg-R58Q mice were stained with hematoxylin and eosin. 
Note that nuclei stain blue with hematoxylin, whereas the cells stain pink/red with eosin. 
Scale bar, 100 m. (B) Enlarged views of the left ventricle and septal tissues of Tg-R58Q hearts. 
Scale bar, 10 m. As indicated, clusters of nuclei could be clearly observed in Tg-R58Q tissues 
compared to control samples suggesting occurrences of the R58Q-mediated degeneration in 
Tg-R58Q myocardium. (C) Microscopic views of left ventricles from Tg-D166V and control Tg-
WT and NTg mice stained with Masson’s trichrome stain (Kerrick et al., 2009). Note the severe 
fibrotic lesions in the myocardium of older 17 months old Tg-D166V mice. Scale bar, 50 m. 
3.2.3 Echocardiography 
Echocardiography, a test in which ultrasound measurements are used to examine the heart, is 
the least invasive method available to screen for cardiac hypertrophy. The echocardiogram 
allows for detailed morphological and functional assessment of the heart. Echocardiography 
examination performed on Tg-E22K mice did not show any major differences between 
transgenic E22K and control WT and/or NTg hearts (Szczesna-Cordary et al., 2005).  
Doppler echocardiography, another technique of ultrasound examination is used to look at 
how blood flows through the heart chambers, heart valves, and blood vessels. It allows 
determination of the velocity and direction of blood flow by utilizing the Doppler effect. 
A 
C B 
www.intechopen.com
Functional Consequences of Mutations in the Myosin  
Regulatory Light Chain Associated with Hypertrophic Cardiomyopathy 
 
395 
Based on the cellular findings, Abraham et al. hypothesized that a malignant FHC 
phenotype associated with the R58Q mutation could be related to diastolic dysfunction of 
the R58Q-mutated myocardium (Abraham et al., 2009). Global diastolic haemodynamics 
were evaluated using transmitral Doppler velocities in Tg-R58Q and Tg-N47K mice and 
compared to controls (NTg and Tg-WT). An apical four-chamber view of the heart was 
obtained. A pulsed Doppler sample was placed at the tip of the mitral leaflets and 
transmitral early (E) and late (A) diastolic velocities and the deceleration time were 
measured and used as noninvasive indicators of global diastolic function (Abraham et al., 
2009). Interestingly, alterations in diastolic transmitral velocities and prolonged deceleration 
time were only noted in Tg-R58Q myocardium (Fig. 7). The authors suggested that the 
malignant FHC phenotype associated with R58Q could be related to abnormal relaxation 
and diastolic dysfunction of the mutated myocardium. The key conclusion of this study was 
that diastolic function is affected earlier in the disease process in the transgenic mouse 
model and may likely be a more sensitive indicator of a malignant FHC phenotype than 
hypertrophy or systolic dysfunction (Abraham et al., 2009).  
 
Control Mutant 
 
Fig. 7. Representative high resolution echocardiography B-mode images from control (A) 
and Tg-R58Q mice (B) show no significant difference in chamber dimensions or wall 
thickness. Representative pulsed Doppler tracings of the mitral valve in controls (C) and Tg-
R58Q mice (D) demonstrating reduced E wave velocity and longer deceleration times in the 
latter group (Abraham et al., 2009).   
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3.2.4 Perfused working heart model 
The hearts of transgenic mice carrying different RLC mutations were tested for the ability to 
perform work under conditions of physiologically relevant levels of metabolic demands and  
for glucose and fatty acid oxidation measured in isolated working hearts (Abraham et al., 2009; 
Szczesna-Cordary et al., 2007). Studies with Tg-E22K mice showed a similar energy metabolism 
pattern compared to control Tg-WT and NTg mouse hearts, but following 20 minutes of no 
flow ischemia, the E22K hearts demonstrated a slightly better recovery compared to WT hearts 
(Szczesna-Cordary et al., 2007). In another study with Tg-R58Q and Tg-N47K mice, it was 
shown that cardiac output, cardiac work and cardiac power were drastically compromised 
compared with controls, Tg-WT or NTg mice  (Abraham et al., 2009). Additional data attained 
with Tg-R58Q mice also demonstrated significantly decreased cardiac efficiency in aerobically 
perfused R58Q hearts compared to controls and poor recovery after an acute ischemic episode 
confirming greatly compromised cardiac function in Tg-R58Q mice (Abraham et al., 2009). 
Results from these studies mirrored the severity of the human phenotypes associated with 
R58Q and N47K mutations, with less severe outcomes in N47K patients, while matching the 
malignant phenotype with multiple cases of SCD in R58Q-positive patients.  
3.2.5 Endogenous level of RLC phosphorylation 
The highly conserved Ser-15 in RLC can be reversibly phosphorylated in vivo by Ca2+-
CaM-activated MLCK. Given the role that RLC phosphorylation can play in affecting 
thick filament structure and cardiac contractility, examining the mutation induced effect 
on RLC phosphorylation is important in understanding the effects of any of the FHC 
mutation. Mutations studied in this review can be categorized into two groups based on 
 
 
Fig. 8. The effect of the D166V mutation on the phosphorylation status of RLC and Troponin 
I (TnI) in transgenic mouse ventricular extracts blotted with CT-1 antibody recognizing total 
RLC protein and 6F9 antibody recognizing total TnI protein (A) and Mab14 MMS-418R 
antibody recognizing +P-TnI (top panel) and +P-human RLC antibody recognizing +P-RLC 
human (Tg) (bottom panel) (B) (Kerrick et al., 2009). 
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their location in the sequence and the 3D organization of RLC (Fig. 3): N47K and R58Q- 
located close or within the Ca2+ binding site, and A13T, E22K and D166V- located in close 
proximity to the phosphorylation site (Ser-15). The status of phosphorylation was 
examined for transgenic mice carrying the R58Q, N47K and D166V mutations (Abraham 
et al., 2009; Kerrick et al., 2009; Muthu et al., 2010; Muthu et al., 2011). Mouse extracts 
from ventricular tissue were rapidly frozen in liquid nitrogen and analyzed by 
immunoblotting. The phosphorylated Tg-RLC was detected with +P-human RLC 
antibodies (generously provided by Dr. Neal Epstein, NIH), specific for the 
phosphorylated form of the ventricular RLC; followed by a secondary goat anti-rabbit 
antibody conjugated with the fluorescent dye, IR red 800. It was interesting to note that 
the mutations in RLC associated with a malignant phenotype (R58Q and D166V) 
displayed a reduced level of phosphorylation compared to N47K and/or WT. 
The decreased level of phosphorylation coincided with those FHC mutations that are 
associated with a severe phenotype (Fig. 8) (Abraham et al., 2009; Kerrick et al., 2009).  This 
suggested that phosphorylation of the regulatory light chain of myosin could have an 
important physiological role in the regulation of cardiac muscle contraction.  
4. Functional studies using cardiac muscle preparations  
4.1 ATPase assays 
4.1.1 Actin activated myosin ATPase activity 
Myosin’s ability to perform mechanical work, powered by the hydrolysis of ATP, requires 
that the enzymatic and mechanical cycles be coupled. Both the hydrolysis of ATP and the 
generation of force and motion are known to be multi-step processes.  The cross-bridge cycle 
can be broadly divided into states where myosin is strongly or weakly bound to actin. It 
starts with the physiologically short-lived rigor state where myosin is bound strongly to 
actin in the absence of ATP. If ATP or its hydrolysis products are bound (M▫ATP, 
M▫ADP▫Pi), myosin shifts to the weakly bound state. Either prior to or following inorganic 
phosphate (Pi) release, myosin undergoes its power stroke increasing its affinity for actin.   
The actin activated myosin ATPase activity, measured as a function of actin concentration 
was determined for FHC-linked RLC mutants using myosin purified from the mouse hearts 
or RLC-depleted porcine myosin reconstituted with WT or FHC RLC mutant protein. The 
assay consisted of titrating myosin with increasing concentrations of skeletal muscle actin. 
The data were analyzed with the Michaelis-Menten equation yielding the Vmax (maximal 
ATPase rate) and Km (apparent dissociation constant) parameters. 
 This assay was performed to understand the effect of the N47K and R58Q mutations on the 
cross bridge cycle (Greenberg et al., 2009). The maximal ATPase rates (Vmax) for NTg (0.43 
s−1) and Tg-WT (0.43 s−1) were seen to be similar to those of RLC carrying the N47K 
mutation (0.43 s−1). However, Tg-R58Q showed a significant increase in Vmax (0.63 s−1). On 
the other hand, a significant decrease in Vmax was observed in Tg-A13T mice (0.38 s-1) 
compared to Tg-WT (0.51 s-1) or NTg (0.63 s-1) mice (unpublished data). The observed 
changes in the ATPase activity for the mutant RLC compared to controls suggest that the 
total amount of free ATP in the cell may vary affecting several ATP dependent processes in 
the heart and leading to the development of FHC phenotype.  Moreover, as Vmax represents 
the rate constant of the transition from the weakly to strongly bound myosin cross-bridges, 
the FHC mutations are expected to affect the kinetics of force generating myosin cross-
bridges and muscle contraction.  
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4.1.2 Myofibrillar ATPase activity 
To understand the effect of mutations in RLC at the myofibrillar level, assays were 
performed on two types of systems: porcine myofibrils reconstituted with the FHC mutant 
or cardiac myofibrils prepared from transgenic mice carrying the RLC mutation.  
For the reconstituted myofibrillar assays, porcine cardiac myofibrils (CMF) were depleted of 
RLC using Triton and CDTA (Szczesna-Cordary et al., 2004a). The CDTA extraction method 
resulted in about 80% depletion of the endogenous RLC. These RLC depleted CMF were 
then reconstituted with exogenous recombinant human cardiac RLC-WT and FHC mutants 
(A13T, F18L, E22K, N47K and R58Q). The authors observed that myofibrils lacking the RLC 
demonstrated dramatic impairment of the Ca2+ regulation of ATPase activity at pCa 8 (low 
Ca2+) and 4.5 (high Ca2+) and also demonstrated lower Ca2+ sensitivity of ATPase. The latter 
was determined to be due to partial extraction of  troponin C (TnC) that occurs during RLC 
extraction. Reconstitution of the RLC-depleted CMF with cardiac TnC and RLC (WT or FHC 
mutant) recovered the Ca2+ regulation of ATPase activity, however; the maximal level of 
ATPase activation was slightly different for various FHC mutants with the highest level 
observed for R58Q-reconstituted CMF. As presented in Table 3, Ca2+ sensitivity of 
myofibrillar ATPase activity was significantly increased for N47K mutant, slightly increased 
for E22K and R58Q, slightly decreased for F18L whereas no change was monitored for A13T 
mutant. It is interesting to note that three of the mutants (N47K, E22K and R58Q) that 
increased the Ca2+ sensitivity of ATPase were seen to either decrease the affinity for Ca2+ or 
to inactivate the  Ca2+ binding site of the human cardiac RLC (Szczesna-Cordary et al., 
2004a; Szczesna et al., 2001).  
Myofibrils from mouse ventricular, septal and papillary muscles of NTg, Tg-WT, Tg-E22K, 
Tg-R58Q and Tg-N47K mice were examined for their Ca2+ sensitivity of ATPase 
activity(Abraham et al., 2009; Szczesna-Cordary et al., 2005). Tg-WT and NTg myofibrils 
showed similar pCa50 when compared among themselves. This established that the Ca2+ 
sensitivity was not RLC-isoform (human versus mouse)-dependent. A statistically significant 
increase in the Ca2+ sensitivity of myofibrillar ATPase activity was observed between NTg 
or Tg-WT mice and Tg-E22K mice  (pCa50≅0.14) (Szczesna-Cordary et al., 2004a). Studies 
on myofibrils from Tg-N47K and Tg-R58Q showed a decrease in the cooperativity of the 
actin–myosin interaction with a much more dramatic effect exhibited by the R58Q mutation. 
Though these results reflect what was seen with porcine CMF reconstituted with FHC 
mutants, the effect seemed to be more pronounced in Tg mice.  Recent studies also showed 
that the maximal ATPase activity in myofibrils from Tg-D166V mice were significantly 
lower when compared to WT. However, it is interesting to note that following 
phosphorylation, the low levels of ATPase activity observed in Tg-D166V was recovered to 
the level of Tg-WT (Muthu et al., 2011). The latter study brought to light the beneficial role 
that RLC phosphorylation may have on cardiac function. More details on the role of Ca2+ 
binding and phosphorylation of the regulatory light chain on the cross bridge cycle are 
discussed later in this review.  
4.2 Studies on cardiac muscle fibers 
To test the functional consequence of FHC mutations at higher levels of organization, 
cardiac papillary muscle fibers from transgenic mice or RLC-depleted and mutant  
reconstituted porcine cardiac papillary muscle fibers were used in steady-state force and 
ATPase measurements.   
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i. Porcine cardiac papillary muscle fibers reconstituted with mutant RLC: Endogenous 
RLC was depleted from porcine cardiac muscle fiber preparations using CDTA and 
Triton (Szczesna-Cordary et al., 2004a). Depletion of endogenous RLC resulted in 
partial extraction of TnC (similar to that seen in porcine CMF). Therefore, TnC was 
added back along with the mutant RLC during reconstitution. It was observed that 
depletion of RLC, which was accompanied by a partial extraction of TnC, resulted in a 
decrease in the maximal level of force development from 100% to ~46%. Reconstitution 
of RLC-depleted fibers with TnC and RLC-WT restored the maximal level of force to 
~84% (Szczesna-Cordary et al., 2004a). FHC mutants (A13T, E22K, N47K and R58Q 
mutants) were then tested for steady-state force development and the regulation of 
Ca2+ sensitivity of force. The lowest level of recovered force was observed for the E22K 
mutant (66%) whereas N47K- and R58Q-reconstituted fibers demonstrated 74% and 
78%, respectively. Also, The E22K mutation was shown to cause a slight increase while 
the two Ca2+ binding site mutants, N47K and R58Q, showed a significantly large 
increase in the Ca2+ sensitivity of force development (Szczesna-Cordary et al., 2004a). 
Interestingly, in studies performed on skinned rabbit psoas muscle fibers reconstituted 
with the E22K mutation, it was observed that the tension at pCa 6.0 and the pCa50 value 
were significantly increased compared to WT-reconstituted psoas fibers (Roopnarine, 
2003).   
These results were in accord with the previous studies by Levine et. al on human biopsy 
samples from patients carrying the E22K mutation. A leftward shift in the tension-pCa curve 
was observed signifying a mutation mediated increase in the Ca2+ sensitivity of force 
development (Levine et al., 1998). Levine's group also studied the structure of the thick 
filaments carrying the E22K mutation compared to normal human fibers isolated from slow 
skeletal muscle. The authors speculated that because the E22K mutation occurs due to the 
substitution of a positively charged residue for a residue that is acidic, an ordered state of 
myosin cross-bridges was expected in both the mutant as well as normal fibers. However, they 
observed a disordered state of the filaments from the mutant biopsy while the wild type 
filaments from the normal human sample showed an ordered relaxed state (Levine et al., 1998).   
ii. Transgenic cardiac papillary muscle fibers: To avoid difficulties related to the 
extraction/replacement of the RLC in porcine muscle preparations, cardiac papillary 
muscle fibers from transgenic mice expressing RLC mutations were used. The 
Ca2+ sensitivity of force development was first examined in transgenic mice carrying the 
E22K mutation of RLC and the results compared to WT control mice (Szczesna-Cordary 
et al., 2005). The mutation was seen to increase the Ca2+ sensitivity of force development 
compared to WT. In addition, a slight gene-dose effect in the force development was 
observed and the glycerinated skinned muscle fibers from TgE22K L4 expressing 87% 
transgene demonstrated slightly higher Ca2+ sensitivity of force than in Tg-E22K L2 
expressing 67% mutant protein (pCa50=5.65 vs. 5.62) (Szczesna-Cordary et al., 2005). The 
authors concluded that the E22K-mediated structural perturbations in the RLC and 
altered Ca2+-binding-properties were most likely responsible for the abnormal function 
of the mutated myocardium and initiation of hypertrophic response and FHC. 
Similar force measurement studies in papillary muscle fibers from Tg-D166V mice revealed 
that the presence of the D166V mutation, associated with malignant clinical outcomes, 
caused a decrease in maximal force as well as a significant leftward shift in myofilament 
Ca2+ sensitivity compared to Tg-WT (Muthu et al., 2011). This report was also the first to 
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demonstrate the physiological effects of RLC phosphorylation in cardiomyopathic 
transgenic mouse hearts. As expected, a small leftward shift in the force–pCa dependence 
was observed for Tg-WT papillary muscle fibers (Fig.9). In contrast, MLCK-treatment of Tg-
D166V fibers resulted in a large decrease in myofilament Ca2+ sensitivity (Fig.9). Therefore, 
phosphorylation of D166V- diseased muscle reversed the increased Ca2+ sensitivity of force 
and brought it back to the level observed for Tg-WT.  
 
 
Fig. 9. Effect of RLC phosphorylation on the force–pCa relationship in skinned muscle fibers 
from Tg-WT mice and Tg-D166V (Muthu et al., 2011).  
In addition to calcium sensitivity, the authors determined the effect of RLC phosphorylation 
on maximal steady-state force (Muthu et al., 2011). In contrast to Tg-WT, which displayed a 
phosphorylation-induced increase in force, the maximal tension in Tg-D166V papillary 
muscle fibers decreased upon phosphorylation. The authors concluded that 
phosphorylation of myosin RLC could work as a regulator of the acto–myosin interaction in 
both normal and cardiomyopathic hearts. A phosphorylation induced tuning of cardiac 
function in the diseased heart was seen to be different from the healthy heart and was 
anticipated to vary depending on the type and the level of cardiac insult.  
Simultaneous ATPase/force-pCa relationships: Studies were designed to perform simultaneous 
force and ATPase measurements in freshly isolated (not glycerinated) skinned papillary 
muscle fibers from transgenic mice (Kerrick et al., 2009; Wang et al., 2006). ATPase activity 
was measured by the NADH fluorescence method (Guth & Wojciechowski, 1986). In this 
method, the regeneration of ATP from ADP and PEP (phospho-enol-pyruvate) by the 
enzyme PK (pyruvate kinase) is coupled to the oxidation of NADH (fluorescent) to NAD 
(non-fluorescent) by LDH (Griffiths et al., 1980; Takashi & Putnam, 1979). The decrease in 
NADH concentration is detected by a decrease in the fluorescence signal at 450 nm. The 
slope of the linear decrease in NADH concentration is used to calculate ATPase activity. In 
these measurements, force was recorded simultaneously with ATPase. The concentration of 
Ca2+ during ATPase/force measurements was measured with Calcium Green-2 fluorescence 
and the data fit to the Hill equation yielding the pCa50 and Hill coefficient nH values (Kerrick 
et al., 2009; Wang et al., 2006).  
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Skinned muscle fibers from Tg-E22K mice showed a significant (20%) decrease in maximum 
ATPase and force compared to Tg-WT controls (Szczesna-Cordary et al., 2007). However, 
contrary to previously reported studies (Szczesna-Cordary et al., 2005) in glycerinated 
skinned muscle fibers, no significant difference in the pCa50 of force/ATPase-pCa 
relationships was observed between Tg-E22K and Tg-WT mice. Similar studies on skinned 
muscle fibers from Tg-D166V and Tg-R58Q mice showed that compared to Tg-WT, the 
mutations associated with a malignant disease phenotype (R58Q and D166V) caused large 
increases in the Ca2+ sensitivity of ATPase and force while those of benign phenotype 
(N47K) showed no changes in the force/ATPase-pCa dependence (Kerrick et al., 2009; Wang 
et al., 2006). Simultaneous ATPase/force-pCa measurements using freshly skinned papillary 
muscle fibers from Tg-D166V mice demonstrated a large increase in the Ca2+ sensitivity of 
force and ATPase compared to control NTg and Tg-WT mice (Kerrick et al., 2009). In 
addition, the maximal ATPase and force per cross-section of muscle fiber were largely 
decreased in the mutant Tg-D166V fibers compared to controls. The authors proceeded to 
calculate the rate of dissociation of the myosin heads from actin (rate of cross-bridge 
dissociation, “g”) and showed a mutation-dependent dramatic decrease in g at all levels of 
force activation (Kerrick et al., 2009). Additionally, the energy cost per cross-bridge (fiber 
ATPase/force) was slightly higher in Tg-D166V fibers compared to controls although the 
difference between Tg-D166V and Tg-WT fibers was not statistically significant (Kerrick et 
al., 2009). The authors speculated that a slower relaxation rate of cycling myosin cross-
bridges most likely triggered a series of pathological responses resulting in an abnormal 
regulation of cardiac muscle contraction in Tg-D166V mice. 
Studies in intact papillary muscle fibers to monitor the rates and amplitudes of [Ca2+] and force 
transients: In parallel to skinned fiber studies, the measurements of force and calcium 
transients were performed in electrically stimulated intact papillary muscle fibers (Kerrick et 
al., 2009; Wang et al., 2006). These experiments directly addressed potential abnormalities of 
the mutated myocardium of diastolic and systolic function observed in the FHC-mutated 
myocardium. Force and Ca2+ transients were seen to be significantly shortened in Tg-E22K 
intact fibers compared to Tg-WT (Szczesna-Cordary et al., 2007). The authors hypothesized 
that by changing the properties of the RLC Ca2+-Mg2+ binding site, the E22K mutation could 
be affecting the function of RLC as a delayed Ca2+ buffer. Consequently, a faster Ca2+ 
reuptake by the sarcoplasmic reticulum proteins and the shorter duration of [Ca2+] and force 
transients could be expected, both indicative of enhanced muscle relaxation. In line with this 
explanation, the R58Q mutation, which was seen to inactivate the RLC calcium binding site 
for Ca2+ binding, should induce an opposite effect to E22K in intact papillary muscle fibers. 
This was in fact observed and significantly prolonged force and [Ca2+] transients were 
monitored in Tg-R58Q papillary muscles compared to Tg-WT (Wang et al., 2006).  In 
parallel, intact fiber studies on Tg-N47K mutation showed no change in force transients with 
small changes in [Ca2+] transients (Wang et al., 2006).   
In the study on the D166V mutation, the authors investigated whether the slower kinetics of 
force generating myosin cross-bridges, as determined in Tg-D166V skinned papillary 
muscle fibers (above), resulted in slower relaxation measured in intact papillary muscles 
from Tg-D166V mice (Kerrick et al., 2009). It was observed that the rates of force relaxation 
in Tg-D166V muscles were significantly slower than the rates measured in Tg-WT or NTg 
papillary muscle fibers. However, the prolonged force transients in Tg-D166V muscle fibers 
were not paralleled by delayed calcium transients and no differences were observed 
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between [Ca2+] transients of Tg-D166V versus Tg-WT or NTg intact muscle fibers (Kerrick et 
al., 2009). Results of this study suggested several potential D166V-mediated factors that 
could contribute to FHC when placed in vivo. First, a large increase in Ca2+ sensitivity could 
contribute to decreased ventricular filling at high heart rates when the tail end of the first 
Ca2+ transient begins to fuse with the second. Secondly, the slow force relaxation rate of the 
fibers could also start to fuse with the next contraction when heart rates are high also 
contributing to diastolic dysfunction. If severe enough these two factors could affect 
diastolic filling of the heart sufficiently to result in systolic dysfunction, i.e. decrease in 
stroke volume. This ultimately would cause the heart to compensate by increasing wall 
thickness (hypertrophy). Finally, the prediction of decreased twitch force caused by a 
decrease in the time constant for the rate of rise of force would also result in systolic 
dysfunction that could only be compensated for by increases in heart rates. 
Overall, studies in skinned and intact muscle fibers from FHC transgenic animals revealed a 
correlation between the mutant-mediated course of the disease in humans and the extent of 
physiological changes observed in the studies with muscle fibers. Prolonged [Ca2+] and force 
transients in intact Tg-R58Q and Tg-D166V papillary muscles as well as increased Ca2+ 
sensitivity of ATPase/force observed in skinned fibers correlated with a poor prognosis in 
R58Q and D166V mutated patients whose phenotype included SCD. Likewise, the slightly 
prolonged [Ca2+] transient with no alterations in force transient, and no change in Ca2+ 
sensitivity of ATPase/force observed in Tg-N47K mice, correlated with the phenotype of 
hypertrophic cardiomyopathy described for N47K patients, including lack of SCD. 
5. Studies with single molecules 
5.1 In vitro motility assays 
In vitro motility assays were utilized to examine the effects of FHC RLC mutations on the 
biochemical and mechanical properties of myosin isolated from the hearts of transgenic 
mice or reconstituted with the recombinant human cardiac WT or FHC mutant. In the study 
by Greenberg et al., myosin was purified from Tg-N47K and Tg-R58Q mouse hearts and 
used in in vitro motility assays with Tg-WT myosin as a control (Greenberg et al., 2009). 
Unregulated motility assays were used to determine whether the mutations caused any 
changes in the duty cycle and/or actin filament sliding velocity. The principle behind this 
assay was that the actin filament  moves at its maximal velocity when incubated with 
enough myosin to ensure that at least one myosin head is interacting with the actin 
filament at all times. Therefore, the amount of myosin required to achieve maximal velocity 
would give a qualitative measurement of the duty cycle. The authors observed a significant 
increase in velocity caused by the R58Q mutation while no major change in actin sliding 
velocity was observed for Tg-N47K myosin compared to Tg-WT (Greenberg et al., 2009).  
Additionally, the isometric force of the mutant myosins was studied using a frictional 
loading assay (Greenberg et al., 2009). A low affinity actin binding protein, ǂ-actinin, was 
introduced in the assay and the concentration of ǂ-actinin needed to stop the filament 
motility was used as a measurement of myosin isometric force. Tg-N47K myosin showed a 
dramatic reduction in isometric force while a less pronounced decrease in force was seen for 
Tg-R58Q compared to Tg-WT myosins. The authors also determined the effect of RLC 
mutation on the velocity-pCa dependence using actin complexed with the regulatory 
proteins, troponin and tropomyosin (Greenberg et al., 2009). While Tg-R58Q myosin 
showed a significant leftward shift in the calcium sensitivity of velocity, Tg-N47K and Tg-
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WT myosins showed no difference in the velocity-pCa curve. This result was consistent with 
the earlier (Wang et al., 2006) and more recent (Mettikolla et al., 2011) fiber studies using 
papillary muscles from these mice, where a significant increase in the Ca2+ sensitivity of 
force was observed for Tg-R58Q mice. Though both Tg-R58Q and Tg-N47K myosins 
displayed a reduction in isometric force, the authors concluded that the more extreme 
phenotype for R58Q could stem from an increase in myosin ATPase activity (discussed 
above in "Actin activated myosin ATPase assays") (Greenberg et al., 2009). On the other 
hand, study results with myosin isolated from transgenic E22K mice showed no effect of the 
mutation on actin sliding velocity or the velocity-pCa dependence (Szczesna-Cordary et al., 
2007).  
The effect of R58Q and N47K mutations was further tested using porcine myosin depleted 
of endogenous RLC and reconstituted with the mutant (R58Q or N47K) RLC proteins 
(Greenberg et al., 2010). The authors examined the effects of these mutations on the 
mechanical properties of myosin under both unloaded and loaded conditions. They found 
that, whereas the mutant myosins were indistinguishable from the controls (WT or native 
myosin) under unloaded conditions, both R58Q- and N47K-exchanged myosins showed 
reductions in force and power output compared with WT or native myosin. They also 
showed that the changes in loaded kinetics resulted from mutation-induced loss of myosin 
strain sensitivity of ADP affinity (Greenberg et al., 2010). The authors concluded that the 
R58Q and N47K mutations alter the mechanical properties of the myosin neck region, 
leading to altered load dependent kinetics that may explain the observed mutant-induced 
FHC phenotypes (Greenberg et al., 2010). 
5.2 Single molecule detection (SMD) 
The advances in single molecule detection (SMD) by fluorescence techniques were 
employed to study some of the earlier discussed FHC-linked RLC mutations. The advantage 
of SMD includes studying the motion of a small population of myosin cross bridges while 
working in their native environment of the sarcomere. Another advantage of this approach 
is the ability to unambiguously determine the behavior (kinetics, orientation, etc.) of the 
normal versus mutated muscle by observing a few molecules (myosin cross-bridges). Since 
humans are heterozygous for FHC mutations, the distribution of the healthy and diseased 
molecules is random and any collection containing more than a few molecules carries a high 
probability of containing a mixture of healthy and diseased moieties. It is therefore essential 
to use a technique such as SMD which is capable of monitoring properties of single 
molecules without averaging over ensembles of molecules with different properties. 
The E22K substitution was the first FHC-associated mutation in RLC studied by SMD 
(Dumka et al., 2006). Mechanical events were measured by monitoring the anisotropy of 
actin labeled with rhodamine phalloidin. The measurements were done on a small 
population of cross bridges in contracting Tg-WT and Tg-E22K cardiac myofibrils. The 
results showed that the mutation did not significantly affect the time of cross-bridge 
dissociation and had no major effect on the mechanical performance of the cross bridges. 
Another mutation that was studied using SMD was the D166V mutation associated with a 
malignant FHC phenotype (Borejdo et al., 2010; Mettikolla et al., 2009; Muthu et al., 2010). In 
one experiment, myofibrils from Tg-D166V mice were labeled with Alexa 488-phalloidin 
and the measurements of the fluorescence lifetime (average rate of decay of a fluorescent 
species from its excited state) of the actin attached fluorophores were performed. No 
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differences between lifetimes of Tg-WT and Tg-D166V muscle were observed (Mettikolla et 
al., 2009).   
In addition to fluorescence lifetime, a meaningful indicator of the state of muscle that can be 
studied with SMD is the cross-bridge duty cycle (Mettikolla et al., 2009; Muthu et al., 2010). 
It was assumed that a cross-bridge is in its strongly attached to actin state for a period of 
time ts, while it remains in a dissociated or a weakly attached state for a period of time, td. 
The ratio Ψ=ts/(td + ts), was defined as the duty cycle. To measure Ψ, one can follow the 
changes in the environment of a cross-bridge while it undergoes a cycle of association and 
dissociation from actin. In the study by Muthu et al. the authors derived the myosin cross-
bridge kinetic rates by tracking the orientation of a fluorescently labeled single actin 
molecule (Muthu et al., 2010). Orientation (measured by polarized fluorescence) oscillated 
between two states, corresponding to the actin-bound (ts) and actin-free (td) states of the 
myosin cross-bridge. The rate of cross-bridge attachment during isometric contraction 
decreased from 3 s−1 in myofibrils from Tg-WT to 1.4 s−1 in myofibrils from Tg-D166V. The 
rate of detachment decreased from 1.3 s−1 (Tg-WT) to 1.2 s−1 (Tg-D166V). In addition, the 
average value of the duty cycle in isometrically contracting myofibrils from Tg-WT and Tg-
D166V mice was 30% and 50%, respectively (Muthu et al., 2010).  The authors hypothesized 
that the slower kinetics of Tg-D166V myosin cross-bridges could be the result of a mutation-
mediated decrease in endogenous phosphorylation of myosin RLC, as was observed in the 
hearts of Tg-D166V mice (Kerrick et al., 2009). Indeed, the authors showed that the level of 
RLC phosphorylation was largely decreased in Tg-D166V myofibrils compared to Tg-WT 
(Muthu et al., 2010). They concluded that the D166V-induced change in the cross-bridge 
kinetics could further lead to abnormalities in diastolic and/or systolic function that in the 
long term would result in a compensatory hypertrophy and sudden cardiac death, as 
observed in patients harboring the D166V mutation in RLC.  
The SMD technique was further refined in the study by Borejdo et al. (Borejdo et al., 2010). The 
authors analyzed the probability distribution of polarized intensity fluctuations and measured 
fluctuations by recording the parallel and perpendicular components of fluorescent light 
emitted by an actin-bound fluorophore (Borejdo et al., 2010). The histograms of fluctuations of 
fluorescent actin molecules in Tg-WT hearts in rigor were represented by perfect Gaussian 
curves. In contrast, histograms of contracting heart muscle were peaked and asymmetric, 
suggesting that contraction in the heart driven by the interaction of myosin cross-bridges with 
actin occurred in at least two steps (Borejdo et al., 2010). Importantly, there were statistically 
significant differences between the histograms of contracting FHC-linked R58Q and D166V 
cardiac muscle preparations versus corresponding contracting WT hearts. On the basis of these 
results, the authors suggested a simple new method of distinguishing between healthy and 
FHC R58Q and D166V hearts by analyzing the probability distribution of polarized 
fluorescence intensity fluctuations of sparsely labeled actin molecules (Borejdo et al., 2010).  
Further studies using SMD were performed on cardiac myofibrils from Tg-R58Q mice 
(Mettikolla et al., 2011). The results showed that the R58Q mutation resulted in a decrease in 
the rate of cross-bridge binding to actin, dissociation from actin and a decreased rate at 
which the cross-bridge undergoes the power stroke (Mettikolla et al., 2011).  The authors 
hypothesized that slower R58Q cross-bridge kinetics were most likely responsible for the 
lower force measured in Tg-R58Q skinned muscle fibers. The combined data on the R58Q 
mutation led the authors to conclude that the R58Q hearts may be subject to inefficient 
energy utilization and compromised heart performance.  
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6. Concluding remarks and future directions 
With the advent of molecular biology and the ability to clone, express and purify myosin 
RLC and the FHC-linked mutations, it has been possible to begin to reconstruct muscle with 
various RLC mutants to learn about their function in increasingly more complex systems.  
The advance of transgenesis has catapulted the researchers to a new era of research where 
the function of FHC-linked RLC mutations could be studied in vivo in transgenic mouse 
hearts. Using various innovative approaches applied at the single molecule, skinned fiber, 
and intact muscle levels, it has been possible to begin to understand the effect of FHC 
mutations on cardiac function. The presented results indicate that RLC phosphorylation and 
Ca2+ binding to the RLC EF-hand calcium binding site may play important roles not only in 
the physiological performance of the heart, but also in muscle contraction of the diseased 
heart.  The MLCK-dependent phosphorylation of RLC was shown to be critical to maintain 
normal cardiac function and was suggested to be especially important in the adaptive 
responses of the heart to pathophysiological injury. Unraveling the molecular basis of RLC-
mediated cardiac dysfunction can ultimately open new possibilities for an effective 
treatment(s) and efforts should be directed towards developing phosphorylation-mediated 
rescue strategies. Collectively, the results presented in this review provided insight into the 
mechanisms underlying the development of FHC disease caused by the mutations in the 
cardiac RLC. Future investigations should be focused on the preventive treatments to 
alleviate or reverse the detrimental effects of all identified RLC mutations. 
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